Identifying the right care plan is CHALLENGING for IgG4-RD patients. There are no FDA-approved treatments for their disease, so patients must rely on off-label medications.

But as new, FDA-approved treatments become available, utilization management TACTICS POSE A THREAT TO PATIENT ACCESS.

POLICIES MUST PROTECT IgG4-RD PATIENTS from harmful delays or denials.

Insurers’ tactics shouldn’t stand between IgG4-RD patients and TIMELY TREATMENT.